CD19 and acute lymphoblastic leukemia: For example, Jin et al. recently developed an autologous HIS mouse model of anti-CD19 CAR-T cell therapy, in which immunocompromised NSG mice were reconstituted with a functional human immune system that was genetically matched to B-lymphoblastic leukemia (B-ALL) [18]